The Day In Review: Biotech Climbs For Second Day In A Row

January 26, 2005 -- In Wednesday’s trading, stocks added on to their gains from yesterday, bouncing off the lows set at Monday’s close. The Centient Biotech 200 climbed 52.74 points to 3322.74, a 1.61% increase . In today's news, Lilly's Q4 numbers were a penny ahead of estimates before charges, Novartis (one of our favorite stocks) reported good results for its breast cancer drug, EntreMed continued to climb on its cancer drug, Connectics moved up after beating estimates, Marshall Edwards got fast-track designation for its prostate cancer drug, ID Biomedical reported good results for its staph vaccine, and StemCells slid lower after contamination was found among the approved lines of stem cells. We give details on these stories...